Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of JNJ-39758979 compared with placebo in patients with uncontrolled asthma despite current treatment with inhaled corticosteroids and/or long-acting beta 2-agonist (LABA) and/or montelukast for at least 4 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a two-part study; each part of the study (Part 1 and Part 2) will be approximately 34 weeks in duration including a 4-week screening phase, a 24-week placebo-controlled treatment phase and a six-week follow-up phase. In Part 1, patients will be randomly assigned to receive placebo or JNJ-39758979 300 mg once daily through Week 24. In Part 2, patients will be randomly assigned to 1 of 4 treatment groups to receive treatment with placebo, 30 mg, 100 mg, or 300 mg of JNJ-39758979 once daily through Week 24. Safety assessments and evaluations to determine the efficacy of JNJ-39758979 to reduce the signs and symptoms of asthma will be performed both on a daily basis via electronic diary and at study visits.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo
|
Drug: Placebo
Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
|
| Experimental: JNJ-39758979 30 mg/d
|
Drug: JNJ-39758979 30 mg/d
Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
|
| Experimental: JNJ-39758979 100 mg/d
|
Drug: JNJ-39758979 100 mg/d
Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
|
| Experimental: JNJ-39758979 300 mg/d
|
Drug: JNJ-39758979 300 mg/d
Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
|
Outcome Measures
Primary Outcome Measures
- The absolute change from baseline in percent-predicted prebronchodilator forced expiratory volume (FEV1) at Week 16 in Part 1 and in Part 2. [Baseline, Week 16]
Secondary Outcome Measures
- Change from baseline in Asthma Control Questionnaire (ACQ) at Week 16 in Part 1 and Part 2 [Baseline, Week 16]
- Change from baseline in postbronchodilator percent-predicted forced expiratory volume in 1 second (FEV1) at Week 16 in Part 1 and Part 2 [Baseline, Week 16]
- Change from baseline in daytime asthma diary symptom score at Week 16 in Part 1 and Part 2 [Baseline, Week 16]
- Change from baseline in nighttime asthma diary symptom score at Week 16 in Part 1 and Part 2 [Baseline, Week 16]
- Change from baseline in average rescue medication use at Week 16 in Part 1 and Part 2 [Baseline, Week 16]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Has a diagnosis of asthma for at least 6 months before screening. -Has been receiving inhaled corticosteroids (≤ 1000 µg fluticasone or its equivalent) alone or in conjunction with long-acting Beta 2-agonist (salmeterol, formoterol, etc.) and/or montelukast.
-
Have an ACQ score ≥ 1.5 at screening. - Must be healthy and medically stable on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
-
Must be post-menopausal or if pre-menopausal, must use an acceptable method of birth control.
Exclusion Criteria:
- Has ever had a life-threatening asthma attack including respiratory arrest, intubation, or intensive care unit admission due to asthma. -Has a history of any other chronic respiratory condition including chronic obstructive pulmonary disease, bronchiolitis, bronchiectasis, allergic bronchopulmonary aspergillosis (mycosis), occupational asthma, sleep apnea or pulmonary hypertension.-Has initiated or discontinued allergen immunotherapy within 12 weeks of screening. -Has smoked within 3 years of screening or has a history of smoking ≥ 10 pack years (1 pack year = 20 cigarettes smoked per day for 1 year) or equivalent, or a positive urine cotinine test at Screening. -Has any known malignancy or has a history of malignancy with the exceptions of basal cell carcinoma or squamous cell carcinoma. -Has chronic or recurrent infectious disease, including, but not limited to: active tuberculosis.-Has a clinically significant, acute respiratory infection within 4 weeks of screening. -Has had a substance abuse (drug or alcohol) problem within the previous 3 years.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Investigators
- Study Director: Johnson & Johnson Pharmaceutical Research & Development Development, L.L.C. Clinical Trial, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR100710
- 39758979ASH2002
- 2011-003852-37